Gmax Biopharm

What Gmax Biopharm does

Gmax Biopharm is a privately held, clinical-stage biopharmaceutical company founded in 2010 in Hangzhou, China, developing proprietary antibody therapeutics that target G-protein-coupled receptors (GPCRs). The company serves patients with cardiovascular disease (pulmonary arterial hypertension), metabolic disorders (type 2 diabetes, obesity, NASH), chronic and diabetic kidney disease, and oncology indications (ovarian cancer). Its clinical pipeline includes six programs — GMA102 (Glutazumab, anti-GLP-1R for T2D, Phase III), GMA105 (anti-GLP-1R for obesity, Phase Ib/II), GMA301 (Getagozumab, anti-ETa for PAH, Phase Ib), GMA131 (anti-ETa for DKD, Phase I/II), GMA106 (M-Body GIPR antagonist/GLP-1R agonist for obesity/T2DM/NASH, Phase I), and GMA202 (ETa/CD3 bispecific for ovarian cancer, preclinical) — supported by roughly 15 additional early-stage programs and a total of 21 antibody/Bibody candidates.

The company's technology foundation consists of two proprietary platforms: the GPCR Monoclonal Antibody Platform, which overcomes historical challenges of generating functional antibodies against difficult GPCR antigens, and the M-Body/Bibody Platform, a modular multispecific architecture that fuses functional motifs to antibody scaffolds to engage two or more signaling pathways simultaneously. The platforms have produced multiple first-in-class assets (GMA102, GMA301, GMA131, GMA202) and are protected by global IP rights. R&D and commercialization activities are coordinated across wholly-owned subsidiaries in Hangzhou (headquarters and R&D), Zhengzhou (manufacturing), Sydney (Australia/NZ clinical operations, Gmax Biopharm Australia Pty Ltd), Thousand Oaks, California (US clinical and business development, GenThera Inc.), and Louvain-la-Neuve, Belgium (European clinical development at the China-Belgium Technology Park).

Gmax Biopharm is pre-revenue and derives no income from commercial product sales; its capital base comes from a CNY 43 million Series A (December 2014, at a CNY 500 million valuation) and a USD 78 million Series C (March 2021, led by China Merchants Group with Tigermed, Parkland Medtech, Cowin Capital, and Ziyao Fund). The planned revenue model rests on direct global commercialization of approved antibody products in major markets supplemented by out-licensing — exemplified by the 2024 out-license of ALV-100 (GMA106) ex-greater China rights to Alveus Therapeutics, which closed a $197M Series A to advance the asset. Clinical execution is supported by partnerships with Nanjing Drum Tower Hospital (lead site for GMA102 Phase III), Peking Union Medical College Hospital and Beijing Xiehe Hospital (PAH trials), Labcorp Drug Development (international CRO), and Tigermed (clinical CRO and investor), with the Zhengzhou facility under construction representing a $250M commitment toward in-house commercial manufacturing capacity (target: 25 million mAb doses per year).

Name

Gmax Biopharm

Legal name

Gmax Biopharm LLC (鸿运华宁（杭州）生物医药有限公司)

Website

https://gmaxbiopharm.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Short description

Gmax Biopharm is a privately held, clinical-stage Chinese biopharmaceutical company developing proprietary GPCR antibody therapeutics for cardiovascular, metabolic, kidney, and oncology indications, with concurrent clinical development across China, the US, Europe, and Australia.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Bispecific & Multispecific Antibodies (HLAAAAAF), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• GPCR antibody therapeutics
• Monoclonal antibody drugs
• Biopharmaceutical drug development
• Metabolic disease therapeutics
• Cardiovascular antibody therapy

Headquarters

HQ city

Hangzhou

HQ country

China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Gmax Biopharm is a clinical-stage biopharmaceutical company. All current revenue is derived from R&D activities. The company does not yet have commercialized products. Planned revenue will come from global sales of antibody drug products upon regulatory approval. The company holds global IP rights for all pipeline assets.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Gmax Biopharm is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics targeting G-protein-coupled receptors (GPCRs) for cardiovascular diseases (PAH, heart failure), metabolic disorders (type 2 diabetes, obesity, NASH), kidney disease (DKD/CKD), and cancer (ovarian cancer). The company leverages two proprietary technology platforms—the GPCR Monoclonal Antibody Platform for generating functional antibodies against historically difficult GPCR targets, and the M-Body/Bibody multispecific platform for engineering multi-pathway antibody therapeutics with improved efficacy and reduced toxicity. All pipeline assets are proprietary with global IP rights and include multiple first-in-class candidates currently in clinical development.

Product overview

Gmax Biopharm is a clinical-stage biopharmaceutical company developing antibody drugs targeting GPCRs (G-protein-coupled receptors). Their portfolio includes GMA102 (Glutazumab) for Type 2 diabetes, GMA105 for obesity, GMA301 (Getagozumab) for pulmonary arterial hypertension, GMA131 for diabetic kidney disease, and M-Body candidates GMA106 (obesity/T2DM/NASH) and GMA202 (ovarian cancer). The company operates two proprietary technology platforms: the GPCR Monoclonal Antibody Platform for generating functional GPCR antibodies, and the M-Body Platform for developing multispecific drugs that engage multiple signaling pathways to improve efficacy and broaden therapeutic indications.

Differentiator

Problem solved

Functional benefit

Products and services

• GMA102 (Glutazumab) Humanized anti-GLP-1R monoclonal antibody carrying a GLP-1 fragment for the treatment of Type 2 diabetes. A biased GLP-1 agonist with less on-target toxicity, supporting bi-weekly dosing (Q2W). Phase III in China for T2D combined with metformin.
• GMA105 Humanized anti-GLP-1R monoclonal antibody carrying a GLP-1 fragment for obesity treatment. First long-lasting GLP-1 antibody agonist, with potential for weekly or bi-weekly dosing. Currently in Phase Ib/II in China.
• GMA301 (Getagozumab) Humanized monoclonal antibody against endothelin receptor A (ETa) for the treatment of pulmonary arterial hypertension (PAH). First antibody drug developed for PAH, with FDA Orphan Drug Designation. Supports monthly dosing (half-life 500-570 hours).
• GMA131 Humanized monoclonal antibody specifically against ETa for diabetic kidney disease (DKD). Global first ETa-specific monoclonal antibody, approved by US FDA for clinical study. Same molecule as GMA301 with ETa specificity.
• GMA106 M-Body targeting both GIPR and GLP-1R for obesity, NASH, and T2DM treatment. Dual pathway regulation decreases appetite and body fat accumulation through anti-GIPR antibody fused with GLP-1 peptide, with potential for weekly or monthly dosing. Showed ~20% body weight reduction in preclinical obese monkey study.
• GMA202 M-Body composed of anti-ETa monoclonal antibody and anti-CD3 antibody fragment, simultaneously targeting ETa and CD3 for ovarian cancer immunotherapy. Pair-matches activated T cells with ETa-overexpressing ovarian cancer cells for precise immunotherapy. Orphan drug candidate for ovarian cancer patients with high ETa expression.

Quantifiable outcome

• GMA102 demonstrated half-life of >230 hours supporting bi-weekly or monthly dosing in clinical trials
• +3 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Peking Union Medical College HospitalcoreImplementation/ SI/ Consulting PartnerLeading clinical research institution partnership for GPCR antibody clinical trials. Peking Union Medical College Hospital is recognized as a national rare disease collaboration and diagnosis center.
• Nanjing Drum Tower HospitalcoreImplementation/ SI/ Consulting PartnerLead institution for GMA102 Phase III clinical trial in Type 2 Diabetes. Principal Investigator: Prof. Zhalong Zhu, Chairman of Chinese Diabetes Society.
• TigermedcoreImplementation/ SI/ Consulting PartnerStrategic partnership for clinical development. Tigermed participated in the Series C financing round. Clinical CRO partnership for accelerating clinical trials.
• Labcorp Drug Development (Covance)coreImplementation/ SI/ Consulting PartnerLeading global CRO selected for GMA301 international multi-center Phase Ib clinical trial in PAH patients. Provides clinical development services and expertise for cardiovascular innovative biopharmaceuticals.
• Clinical Service CenterminorImplementation/ SI/ Consulting PartnerClinical service partnership for trial support services.
• JSBIOminorImplementation/ SI/ Consulting PartnerBiopharmaceutical/biotechnology partnership for development support.
• China Merchants Group Health Division (招商局集团健康板块)coreStrategic or Co-development PartnerStrategic cooperation signed in March 2021 alongside Series C financing. Partnership covers new drug R&D promotion, digital manufacturing base development, and product market expansion with full-chain cooperation.
• TigermedcoreImplementation/ SI/ Consulting PartnerStrategic cooperation agreement signed April 2020 for full-process cooperation in clinical research and development, including clinical monitoring, data management, statistics, medical affairs, pharmacovigilance, quality control, and PK sample testing.
• Alveus TherapeuticscoreOEM/ Whitelabel/ Licensing PartnerGmax Biopharm International Limited out-licensed global development and commercialization rights for ALV-100 (bifunctional GIPR antagonist/GLP-1R agonist fusion protein) outside greater China to Alveus Therapeutics in 2024. Alveus raised $197M Series A to advance ALV-100.
• CBTC (China-Belgium Technology Park)minorStrategic or Co-development PartnerEuropean subsidiary established at CBTC to access European clinical development, partner with EU clusters and R&D partners, and seek regulatory pathway through Belgium for European market.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Eli Lilly: Global pharmaceutical incumbent dominating the GLP-1/incretin space via Mounjaro/Zepbound (tirzepatide) and retatrutide pipeline. Directly relevant as the dominant competitor to Gmax's GMA102, GMA105, and GMA106 programs in T2D/obesity.
• Hansoh Pharmaceutical: Larger established Chinese pharmaceutical company with a broad biologics and small molecule portfolio, including pegmolesatide and several oncology biologics. Comparable as a China-based player investing in innovative biologics, though at much greater scale and commercialization maturity.
• Novo Nordisk: Global pharmaceutical incumbent dominating GLP-1 therapy via Ozempic/Wegovy (semaglutide). Directly relevant as the primary incumbent competitor to Gmax's GLP-1R-targeted antibody pipeline (GMA102, GMA105) and as the established player in obesity/T2DM therapeutics.
• Amgen: Global biopharmaceutical incumbent with extensive biologics franchise including MariTide (AMG 133, GIPR/GLP-1 dual agonist) in obesity. Comparable as both a broad biologics incumbent and the previous employer of Gmax's founder/CEO Dr. Shuqian Jing (15+ years at Amgen).
• United Therapeutics: Established pharmaceutical company specializing in PAH therapies (Tyvaso, Remodulin, Orenitram). Relevant as the dominant commercial incumbent in the same PAH indication targeted by Gmax's lead cardiovascular asset GMA301.

Direct peers

• Innovent Biologics: China-based biopharmaceutical company developing and commercializing high-quality biologics (TYVYT/sintilimab, mazdutide). Comparable as a Chinese biotech with diversified antibody pipeline including GLP-1/incretin candidates (mazdutide) competing in same indications as Gmax's GMA102/GMA106.
• Akeso, Inc. Chinese clinical-stage biopharmaceutical company developing novel bispecific antibodies (e.g., cadonilimab, ivonescimab) using proprietary Tetrabody platform. Highly comparable to Gmax as a China-based innovator with a bispecific antibody technology platform and immuno-oncology/metabolic pipeline focus.
• Mabwell (Jiangsu Mabwell Biopharmaceutical): Clinical-stage Chinese biopharmaceutical company focused on innovative biologics and ADC development. Comparable to Gmax as a Chinese-headquartered biologics innovator targeting oncology and metabolic disease with multiple pipeline candidates.
• Junshi Biosciences: China-based clinical-stage biopharmaceutical company developing innovative antibody therapeutics (toripalimab, JS016) with global out-licensing deals. Comparable as a Chinese innovator biotech with antibody platform, IND-stage assets in major markets, and similar out-licensing strategy.

Emerging players

• Acceleron Pharma: Pulmonary/cardiovascular biologics developer (sotatercept, luspatercept) acquired by Merck in 2021. Comparable as a developer of biologics targeting rare cardiovascular/pulmonary diseases, similar to Gmax's GMA301 PAH program.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries4 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gmax Biopharm